Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Sihuan Pharmaceutical Holdings Group ( (HK:0460) ) just unveiled an announcement.
Sihuan Pharmaceutical Holdings Group Ltd. has successfully completed the spin-off and separate listing of its subsidiary, Xuanzhu Biopharm, on the Main Board of the Stock Exchange of Hong Kong. The listing took place on October 15, 2025, marking a significant milestone for the company as it expands its presence in the biopharmaceutical sector, potentially enhancing its market positioning and providing new opportunities for stakeholders.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
More about Sihuan Pharmaceutical Holdings Group
Sihuan Pharmaceutical Holdings Group Ltd. is a company incorporated in Bermuda, focusing on the pharmaceutical industry. It is involved in the development and distribution of pharmaceutical products and has a market focus on biopharmaceutical advancements.
Average Trading Volume: 82,971,192
Technical Sentiment Signal: Buy
Current Market Cap: HK$15.3B
For an in-depth examination of 0460 stock, go to TipRanks’ Overview page.